Navigation Links
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Date:1/29/2009

MOUNTAIN VIEW, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has consolidated its operations, with a primary focus on the continued rapid development of AZ-004 (Staccato loxapine). The restructuring includes a workforce reduction of 52 employees, representing approximately 33% of the Company's total workforce. In addition, Alexza and Endo Pharmaceuticals, Inc. have agreed to mutually terminate their development agreement for AZ-003 (Staccato fentanyl), a product development candidate that has completed Phase 1 clinical testing. Alexza does not intend to commit additional resources to AZ-003 during 2009.

Alexza expects to reduce its expenses by approximately $21.5 million, net of severance costs, for fiscal year 2009, compared to fiscal year 2008, and approximately $11.1 million for fiscal year 2010, compared to fiscal year 2009. As of September 30, 2008, Alexza had $78.0 million in cash and investments. As a result of this consolidation, Alexza projects that it has available cash resources to maintain its currently planned operations into the second quarter of 2010.

AZ-004 is Alexza's lead product candidate, which is in late-stage clinical development for the acute treatment of agitation in patients with schizophrenia or bipolar disorder. The Company has previously announced positive results in both of its two Phase 3 trials of AZ-004, and expects to submit a New Drug Application for AZ-004 in early 2010. AZ-004 is being developed through Symphony Allegro, a product development partnership formed between Alexza and Symphony Capital, LLC.

"The most difficult aspect of these hard decisions is the fact that Alexza has accomplished much in the past five years as a result of an incredible amount of hard work and dedication by many emp
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
9. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
10. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
11. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... MURRAY HILL and NEW PROVIDENCE, ... North America, Inc. is a corporate sponsor for ... benefits its sister organization, the MassBioEd Foundation. The event ... Pinehills Golf Club in Plymouth, Massachusetts ... and biotechnology education in Massachusetts ...
(Date:9/2/2014)... of what happens on the surface of cells. The ... A group of researchers from Lund University in Sweden ... a large number of vertical nanowires, known as a ... cell and its surroundings takes place through the cell ... the cell together and that largely comprises lipids, built ...
(Date:9/2/2014)... Persistence Market Research ( http://www.persistencemarketresearch.com/ ... Biopharma and Life Sciences: North America ... technology market for pharmaceutical, biopharma and life sciences is estimated ... to grow at a CAGR of 9.1% from 2014 ... 10,886.0 million in 2019. Browse the full ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Myriant ... the signage of a distribution agreement with Azelis ... now distributing Myriant’s bio-succinic acid in the Nordics, ... Ireland, targeting customers in the industrial and base ... powerhouse, Azelis offers a far-reaching chemical portfolio with ...
Breaking Biology Technology:Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3Nano-forests to reveal secrets of cells 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2
... ET, MOUNTAINSIDE, N.J., Feb. 26 National ... that its President,Michael Cohen will present a Keynote ... Institutions and Development Stage,Biotech Companies," at the Inaugural ... Collaborations & Careers in Stem Cell Science,February 28- ...
... 26 Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... the science of healthy aging, today announced,that results of ... February issue of the Journal of Drugs in Dermatology., ... and tolerance of,topical Pyratine-6(TM) over 12 weeks for improving ...
... BioVascular, Inc., a company focused,on developing novel ... Christopher M. Bussineau, Ph.D., to the,position of vice ... position of vice president, business development and nonvascular,operations., ... skill and experience to,BioVascular that will allow us ...
Cached Biology Technology:National Stem Cell Holding, Inc. to Present Keynote Address at The Stem Cell Partnering Series Inaugural Meeting in San Diego 2National Stem Cell Holding, Inc. to Present Keynote Address at The Stem Cell Partnering Series Inaugural Meeting in San Diego 3Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology 2Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology 3BioVascular, Inc. Expands Executive Team 2
(Date:9/2/2014)... their propensity for eating anything, including each other, camel ... from North Carolina State University finds that non-native camel ... United States. , "The good news is that camel ... to humans," says Dr. Mary Jane Epps, a postdoctoral ... paper about the research. , The research stems from ...
(Date:9/1/2014)... us fat? An increasing amount of research shows an ... a more sedentary lifestyle. Now, a new Cornell University ... Some TV programs might lead people to eat twice ... you,re watching an action movie while snacking your mouth ... lead author on the new article just published in ...
(Date:9/1/2014)... after birth, every child in the U.S. undergoes a ... conditions, including sickle cell disease. Thousands of children born ... many suffer and die from the disease each year. ... to at least some of those deaths. , ... in the lab of George Whitesides, the Woodford L. ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Can action movies make you fat? 2Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... nearly complete collection of genes for a species of reef-building ... from The University of Texas at Austin. The scientists ... corals from around the world and how they respond, at ... of the most important questions for coral biologists is whether ...
... A genetic variant that substantially improves survival of ... Lou Gehrig,s disease, has been indentified by a consortium ... of Neurology and Robert Brown, MD, DPhil, Chair and ... School. Discovery of the KIFAP3 gene variant is reported ...
... ambitious effort in avian conservation is underway this spring ... watershed. A legion of highly skilled volunteer ornithologists ... best stopover sites for migrating birds in the southern ... on Neotropical migrants. These songbirds summer in the subarctic ...
Cached Biology News:Most extensive genetic resource for reef-building coral created 2UMMS researchers isolate first 'neuroprotective' gene in patients with amyotrophic lateral sclerosis 2Conservationists seek to identify prime stopover sites for migrating birds 2Conservationists seek to identify prime stopover sites for migrating birds 3
... Includes: Sufficient library for 10 separate ... independent sequences, -28 gIII Sequencing Primer ... -96 gIII Sequencing Primer (100 pmol), ... coli strain ER2738, Control target (Streptavidin) ...
... 15-20 enhancements when used as directed, ... is designed to amplify the desired signal detected by ... proteins with low expression., Membrane Enhancement ... the membrane; 1x solution; 250 ml, ...
... Blot Recycling Kit is effective for ... that have been developed with chemiluminescence ... It is not recommended for stripping ... as it is not possible to ...
... to siRNA library screening, optimal ... identified and verified for each ... CellReady siRNA Transfection Optimization Kit, ... optimizing transfection conditions in 96 ...
Biology Products: